BTSG

BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business.

However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold.

BrightSpring Health Services is leveraging AI and automation across hiring, intake, documentation, and patient care to improve productivity. The company reported 44% year-over-year adjusted EBITDA growth with margin expansion to 5.3%, with further benefits expected in late 2026 and early 2027. Peers Option Care Health and Addus HomeCare are similarly implementing AI-driven initiatives to enhance efficiency and reduce operational complexity.

BrightSpring Health Services (BTSG) receives a #2 (Buy) rating from Zacks with an A VGM Score and B Value Style Score. The company, a national home and community-based healthcare services provider, has seen three analysts revise earnings estimates upward in the last 60 days, with consensus estimates increasing to $1.82 per share and an average earnings surprise of +16.1%.

Zacks analysts published research on 16 major stocks on October 12, 2026. Oracle faces headwinds from negative free cash flow and intense cloud competition but benefits from AI demand.

American Express shows strong spending and customer acquisition despite rising expenses. Progressive maintains a neutral stance due to normalizing auto pricing and valuation concerns. Additional coverage includes Western Midstream, BrightSpring Health, and Dr. Reddy's Laboratories.

The article examines Carillon Mutual Funds as an alternative to larger mutual fund families, highlighting their diversified lineup and active management strategies. Three funds are recommended based on Zacks rankings and performance metrics: Carillon Eagle Small Cap Growth (HSIIX), Carillon Clarivest International Stock (EISIX), and Carillon Chartwell Small Cap (UMBHX). All three funds offer positive multi-year returns and low expense ratios, though investors are cautioned to consider expenses, risk, and performance consistency before investing.